Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD19-CAR_Lenti in Relapsed/Refractory B-ALL and B-NHL
NCT04787263Phase 2Active, not recruiting
- Start
- Mar 2021
- Primary completion
- Mar 2027
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of CD19-CAR_Lenti T cell in acute lymphoblastic leukemia (ALL), diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma (PMBCL). Started Mar 2021; status: active, not recruiting.
02
Drugs
CD19-CAR_Lenti T cell
03
Conditions
acute lymphoblastic leukemia (ALL)diffuse large B-cell lymphoma (DLBCL)primary mediastinal large B-cell lymphoma (PMBCL)
Beyond the preview
Go deeper on NCT04787263.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04787263.